Why have we decided the fair price of the drug is based on ICER analysis rather than something like below?
Cost of devel/# of courses over patent life + manuf cost + reasonable profit +/- time value of money
@VPrasadMDMPH @drjohnm @AnkurFactorialhttps://twitter.com/CMichaelGibson/status/1257381129751007233 …
The fact that drug companies can operate across most of the world very profitably with drugs a fraction of the cost of the US suggests that high prices are not a necessary precondition for the market to exist, no matter what the companies loudly proclaim
-
-
I'm not sure I would take it that far.
-
Marginal costs can be lower after fixed costs are paid for. Question is whether US should be responsible for such a large share of fixed costs and whether the QALY approach helps us get a better deal or just feel better about bearing a big chunk than everyone else?
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.
That being said, the only people it really serves if the pricing mechanics become less opaque is the patients, so I suspect the prices won't come down significantly unless the US govt takes action